Peptides for Visceral Fat Loss
Best peptides for visceral fat loss are tesamorelin or tesamorelin blends. It works with the pituitary gland to help your body naturally release more growth hormone. This increases IGF-1 levels and helps reduce deep belly fat around the organs.
You will need to create a free account with the vendor below to be able to order.
Ordering is easy once you have created your account.
REVIEWED BY
Marcus Reinhardt — Chemical Researcher, Lead Analyst & Peptide Research Advisor
Marcus Reinhardt is a chemical researcher specializing in sustainable materials and advanced formulation science, with research experience in compound development and health optimization. He reviews all Peptide Insider educational content for scientific accuracy, strength of supporting evidence, and practical relevance. Editorial team.
How do peptides target visceral and belly fat?
Tesamorelin is unique because it’s the only peptide FDA-approved to specifically reduce visceral fat. It’s sold as Egrifta for excess abdominal fat in adults with HIV-related lipodystrophy.
The compound with the deepest visceral-fat file gets its own page: our tesamorelin for visceral fat guide.
Other peptides, such as AOD-9604 and the combination CJC-1295 + ipamorelin, have been studied for similar effects, but they are not FDA-approved for this purpose.
Does tesamorelin work on visceral fat?
Tesamorelin carries the strongest human dataset of any compound on this site. In pooled Phase 3 trials, HIV lipodystrophy patients showed visceral adipose reductions of roughly 15 to 18 percent over 26 weeks, and a 2014 JAMA trial reproduced the effect while also examining liver fat. The table below is the honest summary.
| Finding | Model |
|---|---|
| 15 to 18 percent visceral adipose reduction | Phase 3 trials, HIV lipodystrophy (2010) |
| Visceral and liver fat effects reproduced | JAMA randomized trial (2014) |
| FDA approval as Egrifta | HIV-associated lipodystrophy only (2010) |
| AOD-9604 human weight trials | Did not meet endpoints |
What this evidence does not cover
The approval is specific to HIV-associated lipodystrophy; no trial supports general fat loss in healthy people, and visceral fat returned after discontinuation in the trials. Research vials are not pharmacy Egrifta, and anything sold as a slimming product is grey market by definition. A batch-matched third-party COA remains the minimum standard.
Primary sources
- Metabolic effects of a growth hormone-releasing factor — Falutz et al., NEJM, 2007
- Pooled Phase 3 tesamorelin analysis — Falutz et al., JCEM, 2010
- Tesamorelin, visceral and liver fat randomized trial — Stanley et al., JAMA, 2014
Scott Palmage is a 34-year-old accountant in South Jordan, Utah, and a reader of this site. He describes himself as slightly overweight, with stubborn fat on his lower abdomen that he wanted to try tesamorelin for. What follows is his account as he gave it to us, reported rather than recommended.
What he did: for the first four weeks he injected 1 mg of tesamorelin a day. From week five he moved to 2 mg a day, taken in the evening, and started a low-carb diet at the same time. He stayed at 2 mg daily through week sixteen. Throughout the four months he lifted weights four times a week. For reference, 2 mg daily is the amount the phase 3 and JAMA trials cited above administered (the trial table is on our tesamorelin dosage calculator), in a population, HIV-associated lipodystrophy, that Scott is not part of.
What happened: over the four months he lost more than 12 pounds on a bathroom scale, and he attributes the loss to fat around his lower abdomen. He did not have a DEXA or other scan, so how much of that weight was visceral fat, as opposed to subcutaneous fat or water, is not something his numbers can tell us.
Side effects, and why it ended: for the first couple of months he noticed none. Around the four-month mark a rash developed at the injection site, and he stopped. The rash is what ended the experiment, not a decision that it had run its course.
What his account can and cannot show: he was lifting weights four times a week throughout and eating low-carb from week five, so the scale result cannot be attributed to tesamorelin alone. What his account does document is a late-appearing injection-site reaction in someone who tolerated the first two months without incident, which is the kind of effect a 26-week trial can record but a first-month impression cannot.
Scott Palmage, South Jordan, Utah
Shared with permission. Scott is a reader of Peptide Insider with no commercial relationship to the site. One person’s self-reported experience — a report, not evidence: no controls, no blinding, and other factors can’t be ruled out. Compounds discussed are sold strictly for non-human research use.
What does tesamorelin cost per mg?
Research-market tesamorelin runs $40 to $90 for a 5 to 10mg vial, about $8 per mg — a fraction of pharmacy grade options.
If you plan to use Tesamorelin for non-research purposes, talk to your physician to get a prescription.
When will I get my order?
- Depending on the vendor you order from, shipping typically takes:
- Amino Club: 3 to 5 Business Days
- EZ Peptides: 5 to 7 Business Days
- Ascension: 5 to 7 Business Days
Side-effect breakdowns for the metabolic compounds that come up most: retatrutide, mazdutide, 5-Amino-1MQ, and SLU-PP-915 — every claim cited.
Ready to order?
Research use only. Third-party tested, shipped in 3 to 5 business days.
Lipo-C injections are often sold alongside these compounds for the same goal; they are not peptides, and our Lipo-C side effects page covers what their ingredient evidence and user reports actually show.